Insmed anticipates over $1 billion in BRINSUPRI revenue for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy INSM?
Insmed Inc's stock rose by 3.01% as it reached a 20-day high, reflecting positive investor sentiment following the company's recent financial report.
The company reported total revenues of $606.4 million for 2025, with strong growth from both BRINSUPRI and ARIKAYCE. Insmed anticipates revenues from BRINSUPRI (brensocatib) to exceed $1 billion in 2026, showcasing confidence in its market potential. Additionally, ARIKAYCE is expected to generate between $450 million and $470 million, indicating robust demand for its products. The company also highlighted ongoing clinical trials and a strong cash position of approximately $1.4 billion, which supports future growth and innovation.
This optimistic outlook on revenue growth and product performance is likely to bolster investor confidence and may lead to further stock appreciation as the market responds to Insmed's strategic plans and financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 143.130
Low
162.00
Averages
219.50
High
263.00
Current: 143.130
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INSM Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: INSM's 52-week low is $60.40 per share, while the high is $212.75, with the last trade at $143.57, indicating significant volatility in its stock price over the past year, reflecting varying market expectations for its future performance.
- Market Trend Observation: The current stock price of $143.57 is close to the 52-week low, which may suggest a lack of investor confidence in the company's future growth, necessitating close monitoring of market dynamics to assess investment risks.
- Technical Indicator Warning: INSM's stock price has fallen below its 200-day moving average, typically viewed as a technical sell signal, potentially leading to increased selling pressure and impacting short-term stock performance.
- Investor Sentiment Assessment: Despite the current stock price being below the 200-day moving average, investors should carefully evaluate market sentiment and the company's fundamentals to decide whether to increase or decrease their holdings at this time.
See More
Insmed Grants Inducement Awards to 85 New Employees
- Inducement Award Plan: Insmed has granted inducement awards to 85 new employees under its 2025 Inducement Plan, which aims to comply with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Stock Units and Options: The new employees received a total of 68,947 restricted stock units and options to purchase 4,710 shares at an exercise price of $149.33 per share, reflecting the company's incentive measures closely tied to market performance.
- Vesting Arrangements: The restricted stock units have a four-year vesting schedule with 25% vesting annually, while the options vest gradually over four years, ensuring employee stability and loyalty during their tenure with the company.
- Company Background: Insmed is a global biopharmaceutical company focused on developing first-class therapies to improve the lives of patients with serious diseases, demonstrating its leadership in the biopharmaceutical industry and ongoing commitment to innovation.
See More
Insmed Grants Inducement Awards to 85 New Employees
- Inducement Award Program: Insmed has granted inducement awards to 85 new employees under its 2025 Inducement Plan, aimed at attracting top talent while complying with Nasdaq listing requirements, highlighting the company's commitment to talent acquisition.
- Stock Units and Options: The new employees received a total of 68,947 restricted stock units and options to purchase 4,710 shares at an exercise price of $149.33 per share, reflecting the company's long-term commitment to employee incentives.
- Vesting Schedule: The restricted stock units have a four-year vesting schedule with 25% vesting annually, while the options vest gradually over four years, ensuring continued employee contributions during their tenure and enhancing retention.
- Company Overview: Insmed is a global biopharmaceutical company focused on developing innovative therapies for serious diseases, dedicated to improving patient quality of life, showcasing its leadership and social responsibility in the industry.
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
Insmed's Q4 Update Boosts Confidence in Brinsupri Launch Trajectory
- Confidence in Launch: Insmed's Q4 update highlights the progress of Brinsupri's market launch, indicating strong confidence in the product's trajectory, which is expected to drive future revenue growth for the company.
- Market Demand Expectations: With supportive clinical data for Brinsupri, Insmed anticipates attracting more patients, thereby solidifying its market position in the relevant therapeutic area.
- Financial Performance Outlook: Although specific financial figures were not disclosed, Insmed's update suggests a positive revenue inflow in the upcoming quarters, bolstering investor confidence.
- Strategic Development Focus: Insmed's Q4 update reflects not only confidence in Brinsupri but also the company's ongoing commitment to investment and innovation in the biopharmaceutical sector, aiming to address unmet medical needs.
See More
US Stocks Close Lower Amid AI Outlook Concerns
- Market Weakness: The S&P 500 index fell by 0.28%, the Dow Jones Industrial Average decreased by 0.54%, and the Nasdaq 100 index dropped by 0.41%, indicating market concerns over the outlook for artificial intelligence, particularly affecting chipmakers and AI infrastructure stocks.
- Mixed Economic Data: Initial jobless claims in the US fell to 206,000, a 5-week low, indicating a strong labor market; however, the December trade deficit widened to $70.3 billion, exceeding expectations, reflecting uncertainties in economic recovery.
- Shifts in Fed Policy Expectations: Hawkish comments from Fed officials suggest a potential need for interest rate hikes to combat persistent inflation, leading to a more hawkish outlook for future rate paths, which further dampens market sentiment.
- Earnings Season Nearing Conclusion: With over three-quarters of S&P 500 companies reporting, 74% exceeded expectations, and Q4 earnings are projected to grow by 8.4%, demonstrating corporate resilience, yet the market remains cautious about future growth prospects.
See More
INSM Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: INSM's 52-week low is $60.40 per share, while the high is $212.75, with the last trade at $143.57, indicating significant volatility in its stock price over the past year, reflecting varying market expectations for its future performance.
- Market Trend Observation: The current stock price of $143.57 is close to the 52-week low, which may suggest a lack of investor confidence in the company's future growth, necessitating close monitoring of market dynamics to assess investment risks.
- Technical Indicator Warning: INSM's stock price has fallen below its 200-day moving average, typically viewed as a technical sell signal, potentially leading to increased selling pressure and impacting short-term stock performance.
- Investor Sentiment Assessment: Despite the current stock price being below the 200-day moving average, investors should carefully evaluate market sentiment and the company's fundamentals to decide whether to increase or decrease their holdings at this time.
See More
Insmed Grants Inducement Awards to 85 New Employees
- Inducement Award Plan: Insmed has granted inducement awards to 85 new employees under its 2025 Inducement Plan, which aims to comply with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Stock Units and Options: The new employees received a total of 68,947 restricted stock units and options to purchase 4,710 shares at an exercise price of $149.33 per share, reflecting the company's incentive measures closely tied to market performance.
- Vesting Arrangements: The restricted stock units have a four-year vesting schedule with 25% vesting annually, while the options vest gradually over four years, ensuring employee stability and loyalty during their tenure with the company.
- Company Background: Insmed is a global biopharmaceutical company focused on developing first-class therapies to improve the lives of patients with serious diseases, demonstrating its leadership in the biopharmaceutical industry and ongoing commitment to innovation.
See More
Insmed Grants Inducement Awards to 85 New Employees
- Inducement Award Program: Insmed has granted inducement awards to 85 new employees under its 2025 Inducement Plan, aimed at attracting top talent while complying with Nasdaq listing requirements, highlighting the company's commitment to talent acquisition.
- Stock Units and Options: The new employees received a total of 68,947 restricted stock units and options to purchase 4,710 shares at an exercise price of $149.33 per share, reflecting the company's long-term commitment to employee incentives.
- Vesting Schedule: The restricted stock units have a four-year vesting schedule with 25% vesting annually, while the options vest gradually over four years, ensuring continued employee contributions during their tenure and enhancing retention.
- Company Overview: Insmed is a global biopharmaceutical company focused on developing innovative therapies for serious diseases, dedicated to improving patient quality of life, showcasing its leadership and social responsibility in the industry.
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
Insmed's Q4 Update Boosts Confidence in Brinsupri Launch Trajectory
- Confidence in Launch: Insmed's Q4 update highlights the progress of Brinsupri's market launch, indicating strong confidence in the product's trajectory, which is expected to drive future revenue growth for the company.
- Market Demand Expectations: With supportive clinical data for Brinsupri, Insmed anticipates attracting more patients, thereby solidifying its market position in the relevant therapeutic area.
- Financial Performance Outlook: Although specific financial figures were not disclosed, Insmed's update suggests a positive revenue inflow in the upcoming quarters, bolstering investor confidence.
- Strategic Development Focus: Insmed's Q4 update reflects not only confidence in Brinsupri but also the company's ongoing commitment to investment and innovation in the biopharmaceutical sector, aiming to address unmet medical needs.
See More
US Stocks Close Lower Amid AI Outlook Concerns
- Market Weakness: The S&P 500 index fell by 0.28%, the Dow Jones Industrial Average decreased by 0.54%, and the Nasdaq 100 index dropped by 0.41%, indicating market concerns over the outlook for artificial intelligence, particularly affecting chipmakers and AI infrastructure stocks.
- Mixed Economic Data: Initial jobless claims in the US fell to 206,000, a 5-week low, indicating a strong labor market; however, the December trade deficit widened to $70.3 billion, exceeding expectations, reflecting uncertainties in economic recovery.
- Shifts in Fed Policy Expectations: Hawkish comments from Fed officials suggest a potential need for interest rate hikes to combat persistent inflation, leading to a more hawkish outlook for future rate paths, which further dampens market sentiment.
- Earnings Season Nearing Conclusion: With over three-quarters of S&P 500 companies reporting, 74% exceeded expectations, and Q4 earnings are projected to grow by 8.4%, demonstrating corporate resilience, yet the market remains cautious about future growth prospects.
See More
